MAXVAX Biotechnology
China - Chengdu
BiotechnologyFocus: Vaccines & Adjuvants
MAXVAX Biotechnology is a life sciences company focused on Vaccines & Adjuvants.
VaccinesInfectious Diseases
Funding Stage
SERIES C +
Open Jobs
1
Pipeline & Clinical Trials
Low Dose Recombinant Herpes Zoster Vaccine
Herpes ZosterClinical Trials (1)
NCT05636436Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
Phase 1Recombinant Respiratory Syncytial Virus Vaccine
Respiratory Syncytial Virus (RSV)Clinical Trials (1)
NCT06642558Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above
Phase 1/2Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine
Rotavirus InfectionsClinical Trials (1)
NCT05621655Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
Phase 2Low dose Recombinant Herpes Zoster Vaccine
Herpes ZosterClinical Trials (1)
NCT05856084Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
Phase 2Recombinant Zoster Vaccine
Herpes ZosterClinical Trials (1)
NCT07293065Long-term Efficacy of Recombinant Zoster Vaccine (CHO Cell) Study
Phase 3Recombinant Zoster Vaccine
Herpes ZosterClinical Trials (1)
NCT06654700Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).
Phase 3Recombinant Respiratory Syncytial Virus Vaccine
Respiratory Syncytial Virus (RSV)Clinical Trials (1)
NCT07272434Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
Phase 3Recombinant Zoster Vaccine
Herpes ZosterClinical Trials (1)
NCT06447779Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older
Phase 3Open Jobs (1)
Interview Prep Quick Facts
Founded: 2006
Portfolio: 8 clinical trials
Open Roles: 1 active job